Grail Stock Jumps 36% on FDA Staff's Positive Galleri Assessment
Grail shares have spiked 36% after FDA staff issued a positive assessment of the Galleri test, citing its high accuracy and low false-positive rate. TradingView notes that the FDA document confirms the test’s ability to detect multiple cancers at curable stages ahead of the September 23 advisory committee meeting.
TradingView highlights the FDA staff’s specific praise for Galleri’s low false-positive rate and its ability to identify most cancers at stages amenable to curative treatment. The report also details the test’s mechanism as a next-generation sequencing tool designed to detect cancer-specific methylation patterns in blood, targeting adults aged 50 and older.
Source: TradingViewGrail shares surged after FDA staff highlighted the Galleri test's ability to detect multiple cancers at curable stages.
Source: Benzinga
